Skip to content

AbbVie ABBV Income Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$62.82B+2.7%$61.16B+2.5%$59.64B+2.3%$58.33B+1.7%$57.37B+1.8%
$18.42B+1.2%$18.2B+0.9%$18.05B+6.4%$16.96B+0.9%$16.81B-0.5%
$44.4B+3.4%$42.96B+3.3%$41.6B+0.5%$41.37B+2.0%$40.56B+2.9%
70.7%+0.4pp70.2%+0.5pp69.7%-1.2pp70.9%+0.2pp70.7%+0.7pp
$14.3B+2.0%$14.01B+0.3%$13.97B-4.4%$14.61B-0.8%$14.73B-0.1%
$47.49B+3.0%$46.09B-8.9%$50.6B+6.8%$47.36B+0.1%$47.3B+0.2%
$15.33B+1.7%$15.08B
24.4%-0.2pp24.6%
$5.98B-9.4%$6.6B
$2.33B-1.3%$2.36B+422%-$735M+0.8%-$741M-27.5%-$581M-1.9%
$3.64B-14.0%$4.23B+77.0%$2.39B-36.5%$3.76B-10.3%$4.2B-1.9%
5.8%-1.1pp6.9%+2.9pp4%-2.4pp6.5%-0.9pp7.3%-0.3pp
$2.03-14.0%$2.36+78.8%$1.32-37.1%$2.10-10.6%$2.35-2.1%
$2.03-14.0%$2.36+78.8%$1.32-37.1%$2.10-10.6%$2.35-2.1%
7.1B0.0%7.1B0.0%7.1B0.0%7.1B0.0%7.1B0.0%
7.1B0.0%7.1B0.0%7.1B0.0%7.1B0.0%7.1B0.0%
$5.51B+9.9%$5.02B-5.8%$5.33B+95.3%$2.73B-4.0%$2.84B+3.0%
-$2.65B-0.7%-$2.63B-1.7%-$2.58B-3.0%-$2.51B-7.4%-$2.33B-8.1%
-$2.65B-0.7%-$2.63B-1.7%-$2.58B-3.0%-$2.51B-7.4%-$2.33B-8.1%
-$2.65B-0.7%-$2.63B-1.7%-$2.58B-3.0%-$2.51B-7.4%-$2.33B-8.1%
-$6.66B-14.9%-$5.8B-22.4%-$4.74B+12.2%-$5.39B-31.6%-$4.1B-26.5%
$9.5B+4.5%$9.1B-31.6%$13.29B+1.4%$13.1B+1.4%$12.92B+1.0%
$15.33B+1.7%$15.08B
$23.43B+0.7%$23.28B
$23.43B+0.7%$23.28B
37.3%-0.8pp38.1%
$15.33B+1.7%$15.08B

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is AbbVie's revenue?
AbbVie (ABBV) generated $62.8B in revenue over the trailing twelve months, up 9.5% year over year.
Is AbbVie profitable?
AbbVie reported $3.6B in net income over the trailing twelve months, a 5.8% net margin.
What are AbbVie's profit margins?
Gross margin is 70.7% and operating margin is 24.4%, with a 5.8% net margin.
What is AbbVie's earnings per share?
AbbVie's diluted EPS over the trailing twelve months is $2.03.
Where does AbbVie's income statement data come from?
Every line is extracted from AbbVie's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.